Research Summaries

In the phase 3a REIMAGINE 1 trial, once-weekly cagrilintide–semaglutide reduced HbA1c vs placebo at 40 weeks in adults with early-stage type 2 diabetes that was inadequately controlled with diet and...

The FDA approved cefepime and zidebactam (Zaynich, Wockhardt), a novel intravenous antibiotic, for adults with complicated urinary tract infections, including pyelonephritis, caused by susceptible...

A 2-year trial compared tirzepatide with intensified conventional care in adults with early type 2 diabetes.

ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.

Researchers assessed whether GLP-1 exposure was associated with breast cancer incidence among women undergoing screening.

FDA approval gives physicians the first authorized treatment option for adults with chronic hepatitis delta virus infection.

A phase 3 trial found that switching from bictegravir–emtricitabine–tenofovir alafenamide to once-daily bictegravir–lenacapavir maintained viral suppression in adults with HIV-1.

The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...

A recent multicenter trial assessed azithromycin for moderate-to-severe wheezing in preschool children treated in emergency departments.

A pilot trial tested whether brief prescribing support could improve rural primary care professionals' willingness to treat OUD with buprenorphine.